JP2018516983A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516983A5
JP2018516983A5 JP2018513744A JP2018513744A JP2018516983A5 JP 2018516983 A5 JP2018516983 A5 JP 2018516983A5 JP 2018513744 A JP2018513744 A JP 2018513744A JP 2018513744 A JP2018513744 A JP 2018513744A JP 2018516983 A5 JP2018516983 A5 JP 2018516983A5
Authority
JP
Japan
Prior art keywords
composition
nucleic acid
item
hsv
guide rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/034606 external-priority patent/WO2016196273A1/en
Publication of JP2018516983A publication Critical patent/JP2018516983A/ja
Publication of JP2018516983A5 publication Critical patent/JP2018516983A5/ja
Pending legal-status Critical Current

Links

JP2018513744A 2015-05-29 2016-05-27 ウイルス感染を処置するための組成物および方法 Pending JP2018516983A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168259P 2015-05-29 2015-05-29
US201562168262P 2015-05-29 2015-05-29
US62/168,262 2015-05-29
US62/168,259 2015-05-29
PCT/US2016/034606 WO2016196273A1 (en) 2015-05-29 2016-05-27 Compositions and methods to treat viral infections

Publications (2)

Publication Number Publication Date
JP2018516983A JP2018516983A (ja) 2018-06-28
JP2018516983A5 true JP2018516983A5 (enExample) 2019-06-27

Family

ID=57441664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513744A Pending JP2018516983A (ja) 2015-05-29 2016-05-27 ウイルス感染を処置するための組成物および方法

Country Status (4)

Country Link
EP (1) EP3331571A4 (enExample)
JP (1) JP2018516983A (enExample)
CA (1) CA3000189A1 (enExample)
WO (1) WO2016196273A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3324999A1 (en) * 2015-05-29 2018-05-30 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4179085A1 (en) * 2020-07-07 2023-05-17 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof
EP4281184A4 (en) * 2021-01-25 2025-04-30 Fred Hutchinson Cancer Center TREATMENT OF HSV-1 USING A MEGANUCLEASE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting

Similar Documents

Publication Publication Date Title
JP2018516984A5 (enExample)
Lu et al. The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects
Liu et al. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy
Elsabahy et al. Non-viral nucleic acid delivery: key challenges and future directions
Lu et al. Overcoming pharmaceutical bottlenecks for nucleic acid drug development
US20190185882A1 (en) Compositions and Methods of Delivering Treatments for Latent Viral Infections
JP2017518075A5 (enExample)
US20170087224A1 (en) Delivery methods and compositions
US20200230259A1 (en) Isolation of extracellular vesicles (evs) from red blood cells for gene therapy
JP2018516983A (ja) ウイルス感染を処置するための組成物および方法
WO2017147432A1 (en) Antiviral nuclease compositions and methods
JP2018532403A5 (enExample)
Goodwin et al. Nonviral vectors: we have come a long way
KR100817024B1 (ko) 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
JP2020505390A (ja) Crispr治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス
Çiçek et al. Advances in CRISPR/Cas9 technology for in vivo translation
Janssen et al. Gene based therapies for kidney regeneration
JP2025520663A (ja) 交流電場とcrispr-casシステムを用いた症状および疾患の治療システムおよび方法
Liu et al. Towards the elimination of infectious HPV: exploiting CRISPR/Cas innovations
CN102206680A (zh) 基于短链核酸片段的基因电转染缓冲液及其制备和应用方法
Shafi et al. Current Vectors for In Vivo Delivery of CRISPR-Cas9 System
Monet The emergence of the next-generation vaccines
Singh et al. The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions
Massadeh et al. Polymer nanoparticles for targeted gene delivery
Carvalho et al. 152. retinal tropism of exosome-associated AAV vector via intravitreal delivery